Clinical Trial Update: Phase 2 Study of ET-743 (Trabectedin) in Patients With Persistent or Recurrent Endometrial Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 study of trabectedin (ET-743) in patients with persistent or recurrent endometrial carcinoma has completed; the update mentions the trial status but doe…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer
• Uterine Cancer

Drugs mentioned

• Trabectedin (trabectedin)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Endometrial Neoplasms, Uterine Neoplasms | Phase 2 | Status: COMPLETED